Portola Phramaceuticals (PTLA)

[DewDiligence]

Those dates have evidently slipped; according to PTLA’s 1Q15 CC, patient enrollment will not be complete until the end of 2015:

http://seekingalpha.com/article/3150046-portola-pharmaceuticals-ptla-ceo-william-lis-on-q1-2015-results-earnings-call-transcript

We are evaluating betrixaban for extended duration VTE prophylaxis in a global pivotal Phase 3 APEX study, a landmark trial that will advance the field of thrombosis to a precision-based medicine. The trial is over 80% enrolled in more than 450 global sites. Importantly, we remain on track to complete enrollment by year end as planned.